{"DataElement":{"publicId":"6004316","version":"1","preferredName":"International Staging System for Myeloma Stage","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)_The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body._A method of staging myeloma published by the International Myeloma Working Group in 2003._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"2688930v1.0:6003927v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2688930","version":"1","preferredName":"Plasma Cell Myeloma Stage","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)_The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"PLSM_CL_MY_STG","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2647790","version":"1","preferredName":"Myeloma","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) -- 2003","longName":"C3242","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"32446690-9562-2995-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-06-06","modifiedBy":"ONEDATA","dateModified":"2007-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2224086","version":"1","preferredName":"Stage","preferredDefinition":"The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63F1A4F-0A96-5494-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-03","endDate":null,"createdBy":"UMLLOADER_CAMOD","dateCreated":"2005-05-03","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4C63AF-66BE-65EE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6003927","version":"1","preferredName":"International Staging System for Myeloma Stage","preferredDefinition":"A method of staging myeloma published by the International Myeloma Working Group in 2003._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"2689275v1.3","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"7","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Baseline staging not available","valueDescription":"Unavailable","ValueMeaning":{"publicId":"5828000","version":"1","preferredName":"Unavailable","longName":"5828000","preferredDefinition":"The desired information is not available.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Available","conceptCode":"C126101","definition":"The desired information is not available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FA9603A-3882-60D4-E053-F662850A4F9D","latestVersionIndicator":"Yes","beginDate":"2017-05-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-16","modifiedBy":"GDEEN","dateModified":"2024-01-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B6F7C6F-C6AA-5ACE-E053-F662850A4A80","beginDate":"2017-10-13","endDate":null,"createdBy":"RODGERSC","dateCreated":"2017-10-13","modifiedBy":"ONEDATA","dateModified":"2017-10-13","deletedIndicator":"No"},{"value":"I","valueDescription":"ISS Stage I Plasma Cell Myeloma","ValueMeaning":{"publicId":"3928731","version":"1","preferredName":"ISS Stage I Plasma Cell Myeloma","longName":"3928731","preferredDefinition":"Plasma cell myeloma with beta-2-microglobulin less than 3.5 and albumin greater than or equal to 3.5 (median survival of 62 months).  Note that the older Durie/Salmon staging system defines stage I quite differently. (PDQ)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ISS Stage I Multiple Myeloma","conceptCode":"C70658","definition":"Multiple myeloma with beta-2-microglobulin less than 3.5 and albumin greater than or equal to 3.5 (median survival of 62 months).  Note that the older Durie/Salmon staging system defines stage I quite differently. (PDQ)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E97D61EC-FF5F-F81E-E040-BB89AD435714","latestVersionIndicator":"Yes","beginDate":"2013-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B6F7C6F-C6BE-5ACE-E053-F662850A4A80","beginDate":"2007-10-12","endDate":null,"createdBy":"RODGERSC","dateCreated":"2017-10-13","modifiedBy":"ONEDATA","dateModified":"2017-10-13","deletedIndicator":"No"},{"value":"II","valueDescription":"ISS Stage II Plasma Cell Myeloma","ValueMeaning":{"publicId":"2689277","version":"1","preferredName":"ISS Stage II Plasma Cell Myeloma","longName":"2689277","preferredDefinition":"Plasma cell myeloma with beta-2-microglobulin less than 3.5 and albumin less than 3.5 or beta-2-microglobulin 3.5 to less than 5.5 (median survival of 44 months).  Note that the older Durie/Salmon staging system defines stage II quite differently. (PDQ)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ISS Stage II Multiple Myeloma","conceptCode":"C70659","definition":"Multiple myeloma with blood levels of beta-2-microglobulin between 3.5 and 5.5 mg/L.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4DC21A-8C70-4383-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"KUMMEROA","dateModified":"2023-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B6F7C6F-C6D2-5ACE-E053-F662850A4A80","beginDate":"2007-10-12","endDate":null,"createdBy":"RODGERSC","dateCreated":"2017-10-13","modifiedBy":"ONEDATA","dateModified":"2017-10-13","deletedIndicator":"No"},{"value":"III","valueDescription":"ISS Stage III Plasma Cell Myeloma","ValueMeaning":{"publicId":"2689276","version":"1","preferredName":"ISS Stage III Plasma Cell Myeloma","longName":"2689276","preferredDefinition":"Plasma cell myeloma with beta-2-microglobulin greater than or equal to 5.5 (median survival of 29 months).  Note that the older Durie/Salmon staging system defines stage III quite differently. (PDQ)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ISS Stage III Multiple Myeloma","conceptCode":"C70660","definition":"Multiple myeloma with beta-2-microglobulin greater than or equal to 5.5 (median survival of 29 months).  Note that the older Durie/Salmon staging system defines stage III quite differently. (PDQ)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4DC21A-8C49-4383-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"KUMMEROA","dateModified":"2023-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B6F7C6F-C6E6-5ACE-E053-F662850A4A80","beginDate":"2007-10-12","endDate":null,"createdBy":"RODGERSC","dateCreated":"2017-10-13","modifiedBy":"ONEDATA","dateModified":"2017-10-13","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2575365","version":"1","preferredName":"Unknown","longName":"2575365","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F372-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"5B6F7C6F-C6F0-5ACE-E053-F662850A4A80","beginDate":"2009-10-12","endDate":null,"createdBy":"RODGERSC","dateCreated":"2017-10-13","modifiedBy":"ONEDATA","dateModified":"2017-10-13","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2689274","version":"1","preferredName":"International Staging System for Myeloma Stage","preferredDefinition":"A method of staging myeloma published by the International Myeloma Working Group in 2003.:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C70657:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"International Staging System for Myeloma","conceptCode":"C70657","definition":"A method of staging myeloma published by the International Myeloma Working Group in 2003.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4DC186-5382-2DC6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"ONEDATA","dateModified":"2007-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B6F7C6F-C68C-5ACE-E053-F662850A4A80","latestVersionIndicator":"Yes","beginDate":"2017-10-13","endDate":null,"createdBy":"RODGERSC","dateCreated":"2017-10-13","modifiedBy":"MAESKEB","dateModified":"2022-03-01","changeDescription":".created for UAMS cmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3029677","version":"1","longName":"UAMS Clinical Research","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812848","version":"1","longName":"UAMS New CDEs","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"ISS Stage","type":"Preferred Question Text","description":"ISS Stage","url":null,"context":"NCIP"},{"name":"Alliance Text 1","type":"Alternate Question Text","description":"ISS stage at time of enrollment:","url":null,"context":"Alliance"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BA2AA35-038B-48D6-E053-F662850A08FA","latestVersionIndicator":"Yes","beginDate":"2017-10-15","endDate":null,"createdBy":"RODGERSC","dateCreated":"2017-10-15","modifiedBy":"KUMMEROA","dateModified":"2023-09-29","changeDescription":".created for UAMS 10/15/17 cmr","administrativeNotes":"2023.9.29 AQT added per ticket request CADSR0002904. ak","unresolvedIssues":null,"deletedIndicator":"No"}}